Mission Wealth Management LP Acquires 368 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mission Wealth Management LP raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 3.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,454 shares of the biopharmaceutical company’s stock after purchasing an additional 368 shares during the quarter. Mission Wealth Management LP’s holdings in Gilead Sciences were worth $912,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Altfest L J & Co. Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter worth $210,000. Federated Hermes Inc. lifted its position in shares of Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after purchasing an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Gilead Sciences by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter worth $74,000. Finally, Eagle Asset Management Inc. increased its stake in shares of Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after buying an additional 60,697 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several research reports. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Oppenheimer restated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Thursday, June 20th. Barclays cut their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Finally, Morgan Stanley cut their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $83.47.

View Our Latest Stock Report on Gilead Sciences

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $66.69 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The company has a market cap of $83.09 billion, a PE ratio of 185.25, a P/E/G ratio of 2.83 and a beta of 0.18. The business has a 50-day simple moving average of $66.08 and a two-hundred day simple moving average of $72.11. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter last year, the company earned $1.37 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.62%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Recommended Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.